With the National Association of Chain Drug Stores Total Store Expo currently underway in Boston, the Boston Globe published an op-ed in its opinion section, Podium, which was co-authored by Steven Anderson, president and CEO of NACDS and Michael Malloy, PharmD and dean of the MCPHS University School of Pharmacy - Worcester/Manchester.
GlaxoSmithKline announced FDA approval for Arnuity Ellipta (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid medicine for the treatment of asthma in patients 12 years of age and older.
Researchers at the University of California, San Diego School of Medicine concluded that aspirin, in addition to preventing pain and inflammation, actually helps hasten the end of inflammation in a study published this week in the online early edition of PNAS.
PharmaJet, the developer of a needle-free injection technology to administer medications and vaccines to patients, and bioCSL, the maker of Afluria (influenza vaccine) on Tuesday announced the Food and Drug Administration has approved the PharmaJet Stratis 0.5mL Needle-Free Jet Injector for delivery of Afluria in individuals ages 18 years to 64 years.
The Food and Drug Administration has granted tentative approval for Basaglar (insulin glargine injection), which is used to improve glycemic control in adults with Type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with Type 1 diabetes.
Nearly half of women age 45 years or older who experience symptoms of overactive bladder report their current treatment does not address their OAB symptoms, according to a recent survey conducted by The Harris Poll on behalf of Allergan.
High-dose influenza vaccine is 24% more effective than the standard-dose vaccine in protecting persons ages 65 and older against influenza illness and its complications, according to a Vanderbilt-led study published Wednesday in the New England Journal of Medicine.
The majority of Americans report they have had a good year when it comes to their personal health, and are paying more attention to their health compared to just a few years ago, according to From Hope to Cures: PhRMA’s Second Annual National Health Survey.
Sanofi on Monday acquired the rights to Afrezza Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with Type 1 and Type 2 diabetes, from MannKind in a deal that could be worth as much as $925 million.
BD Medical, a segment of BD, on Wednesday announced the retail pharmacy launch of BD AutoShield Duo, the only pen needle with patented dual front- and back-end shields that provides greater convenience and safety before and after injecting.